StockMarketWire.com - UBS today reaffirms its sell investment rating on AstraZeneca PLC [LON:AZN] and raised its price target to 5700p (from 5400p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk